BG-BVN11339
Warning: Last items in stock!
Availability date:
Bovine Interleukin 6 IL-6 ELISA Kit
Recipient :
* Required fields
or Cancel
Assay Range | 78.1-5,000 pg/mL |
Sensitivity | 10 pg/mL |
Specificity | No cross-reaction with other related substances detected |
Size | 96T |
Storage | Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
Assay Principle | Sandwich ELISA |
Sample Volume | 100 µL final volume, dilution factor varies on samples |
Sample Type | Cell culture supernatants |
Detection Method | Chromogenic |
Kit Components
1. Recombinant Bovine IL-6 standard: 2 vials
2. One 96-well plate coated with Bovine IL-6 Ab
3. Sample diluent buffer: 12 mL - 1
4. Detection antibody: 1 vial
5. Streptavidin-HRP: 1 vial
6. Antibody diluent buffer: 12 mL x1
7. Streptavidin-HRP diluent buffer: 12 mL x1
8. Chromogenic solution A: 6 mlx1
9. Chromogenic solution B: 6 mlx1
10. Stop solution: 6 mL x1
11. Washing solution (20x): 25 mL x1
Background
Interleukin 6 (IL-6), also known as B-cell stimulatory factor 2(BSF-2), CTL differentiation factor (CDF), Hybridoma growth factor, or Interferon beta-2 (IFN-beta-2), is a glycosylated cytokine belonging to the IL-6 family. Mature human IL-6 is a 183 amino acid (aa) polypeptide and shares 39% aa sequence identity with mouse and rat IL-6. IL-6 is expressed in many different cells such as CD8+ T cells, fibroblasts, synoviocytes, adipocytes, osteoblasts, megakaryocytes, endothelial cells, sympathetic neurons, cerebral cortex neurons, adrenal medulla chromaffin cells, retinal pigment cells, mast cells, keratinocytes, Langerhans cells, fetal and adult astrocytes, neutrophils, monocytes, eosinophils, colonic epithelial cells, B1 B cells as well as pancreatic islet beta cells.
IL-6 binds to a cell surface heterodimeric receptor complex composed of IL-6 R α and gp130 which is also a common component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. IL-6 is required for fever and the acute phase response in the liver, and it plays an important role in the transition from acute inflammation to either acquired immunity or chronic inflammatory diseases.